Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Seven Phase 3 Randomized Controlled Trials

por Patel, Shrita, Hickman, Anne, Frederich, Robert, Johnson, Susan, Huyck, Susan, Mancuso, James P., Gantz, Ira, Terra, Steven G.
Publicado 2020

Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study

por Miller, Sam, Krumins, Tania, Zhou, Haojin, Huyck, Susan, Johnson, Jeremy, Golm, Gregory, Terra, Steven G., Mancuso, James P., Engel, Samuel S., Lauring, Brett
Publicado 2018

Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study

por Grunberger, George, Camp, Sarah, Johnson, Jeremy, Huyck, Susan, Terra, Steven G., Mancuso, James P., Jiang, Zhi Wei, Golm, Gregory, Engel, Samuel S., Lauring, Brett
Publicado 2017

Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study

por Hollander, Priscilla, Liu, Jie, Hill, Julie, Johnson, Jeremy, Jiang, Zhi Wei, Golm, Gregory, Huyck, Susan, Terra, Steven G., Mancuso, James P., Engel, Samuel S., Lauring, Brett
Publicado 2017

Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose‐lowering agent: An analysis from VERTIS CV

por Dagogo‐Jack, Samuel, Cannon, Christopher P., Cherney, David Z. I., Cosentino, Francesco, Liu, Jie, Pong, Annpey, Gantz, Ira, Frederich, Robert, Mancuso, James P., Pratley, Richard E.
Publicado 2022

Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial

por Wojeck, Brian S., Inzucchi, Silvio E., Neeland, Ian J., Mancuso, James P., Frederich, Robert, Masiukiewicz, Urszula, Cater, Nilo B., McGuire, Darren K., Cannon, Christopher P., Yaggi, Henry Klar
Publicado 2022

Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL r...

por Pratley, Richard E., Eldor, Roy, Raji, Annaswamy, Golm, Gregory, Huyck, Susan B., Qiu, Yanping, Sunga, Sheila, Johnson, Jeremy, Terra, Steven G., Mancuso, James P., Engel, Samuel S., Lauring, Brett
Publicado 2018

Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo‐cont...

por Dagogo‐Jack, Samuel, Liu, Jie, Eldor, Roy, Amorin, Guillermo, Johnson, Jeremy, Hille, Darcy, Liao, Yuqin, Huyck, Susan, Golm, Gregory, Terra, Steven G., Mancuso, James P., Engel, Samuel S., Lauring, Brett
Publicado 2017

Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized tri...

por Dagogo-Jack, Samuel, Pratley, Richard E, Cherney, David Z I, McGuire, Darren K, Cosentino, Francesco, Shih, Weichung J, Liu, Jie, Frederich, Robert, Mancuso, James P, Raji, Annaswamy, Gantz, Ira
Publicado 2021

Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trials

por Cherney, David Z. I., Heerspink, Hiddo J. L., Frederich, Robert, Maldonado, Mario, Liu, Jie, Pong, Annpey, Xu, Zhi J., Patel, Shrita, Hickman, Anne, Mancuso, James P., Gantz, Ira, Terra, Steven G.
Publicado 2020

Cardiorenal Outcomes With Ertugliflozin by Baseline Metformin Use: Post Hoc Analyses of the VERTIS CV Trial

por Cosentino, Francesco, Cannon, Christopher P., Frederich, Robert, Cherney, David Z.I., Dagogo-Jack, Samuel, Pratley, Richard E., Mancuso, James P., Maldonado, Mario, Cater, Nilo B., Wang, Shuai, McGuire, Darren K.
Publicado 2022